Bawankar DL, Deshmane SV, More SM, Channawar MA, Chandewar AV, Shreekanth J.
Bawankar DL, Deshmane SV, More SM, Channawar MA, Chandewar AV and Shreekanth J.
P. Wadhwani College of Pharmacy, Dhamangaon Road, Girija Nagar, Yavatmal-445001 (M.S.)
Volume - 2,
Issue - 4,
Year - 2009
The objective of present investigation was to develop a extended release matrix tablet for Ranolazine in the treatment of chronic angina pectoris using wet granulation technology. HPMC E 15, EC, HPMC phthalate and different Eudragit grades form release layer. All lubricated formulation was compressed using 16.5 × 8mm oval shaped punches. Compressed tablets were evaluated for uniformity of weight, content of active ingredients, friability, hardness, thickness, invitro dissolution using paddle in 0.1 N HCl at 50 rpm for 24 hrs study. All the formulation showed compliance with pharmacopoeial standards. The batch number (F8) showed extended release of drug according to USP limits. Selected formulation (F8) was subjected to stability studies for three months at 400c ± 20c and 75% RH and showed stability with respect to release pattern. The kinetic treatment showed that lease of drug follows diffusion release and Higuchi model. The result of current study clearly indicate, a promising potential of Ranolazine extended release 500 mg tablets as an alternative to conventional dosage form.
Cite this article:
Bawankar DL, Deshmane SV, More SM, Channawar MA, Chandewar AV, Shreekanth J.. Design and Characterization of Extended Release Ranolazine Matrix Tablet. Research J. Pharm. and Tech.2 (4): Oct.-Dec. 2009; Page 756-761.